Related Experiment Video
Updated: May 7, 2026
08:37
Microglia as a Surrogate Biosensor to Determine Nanoparticle Neurotoxicity
Published on: October 25, 2016
7.0K
Zinc utilization by microglia in Alzheimer's disease
Daniel C Shippy1, Sophia F Oliai1, Tyler K Ulland2
1Department of Pathology and Laboratory Medicine, School of Medicine and Public Health, University of Wisconsin, Madison, Wisconsin, USA.
The Journal of Biological Chemistry
|April 22, 2024
Summary
Zinc plays a critical role in Alzheimer's disease (AD) by influencing microglia, the brain's immune cells. Understanding zinc homeostasis offers potential new therapeutic strategies for AD.
Area of Science:
- Neuroscience
- Immunology
- Biochemistry
Background:
- Alzheimer's disease (AD) is characterized by amyloid-β (Aβ) plaques and tau tangles.
- Microglia, the CNS immune cells, can be both neuroprotective and neurotoxic in AD.
- Microglial function is influenced by nutrient and trace metal utilization.
Purpose of the Study:
- To review the role of zinc in AD pathogenesis.
- To explore how zinc homeostasis affects microglial-mediated neuroinflammation.
- To discuss potential therapeutic strategies targeting zinc in AD.
Main Methods:
- Literature review of studies on zinc, microglia, and AD.
- Analysis of the mechanisms of zinc's influence on microglial activation and function.
- Synthesis of current findings on zinc dyshomeostasis in AD.
Main Results:
- Zinc has essential roles in brain health and immunity.
- Zinc dyshomeostasis is implicated in AD pathogenesis.
- Zinc influences microglial activation and neuroinflammatory responses in AD.
Conclusions:
- Zinc homeostasis is a critical factor in microglial-mediated neuroinflammation in AD.
- Targeting zinc metabolism presents a promising avenue for novel AD therapeutic strategies.
- Further research into zinc's role is needed to develop effective treatments for Alzheimer's disease.
Related Concept Videos
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...